“I think that it is upon us as urologists to try to start to embrace this clinical accomplishment, and that being trying to make our patients as stone free as possible,” says Tom Mueller, MD. In this ...

Focal therapy for prostate cancer has shifted from skepticism to optimism over the past decade. Community-based practitioners and academic programs are increasingly adopting focal therapy. The ...

Men's health addresses care gaps for men aged 18-50, focusing on early intervention to prevent serious conditions. Sexual health and fertility issues often motivate men to seek medical care, ...

The TENACIO pump showed significantly faster completion times and greater efficiency than the MS pump in ex-vivo tasks. Surface electromyography was used to measure muscular effort, normalized to ...

PARP Inhibitors in Metastatic Prostate Cancer: Efficacy, Trials, and Combination Therapies ...

Urologists should prioritize discussions about sexual health with female bladder cancer patients, making it a routine part of care. Understanding the impact of bladder cancer treatments on body image ...

PARP Inhibitors in Metastatic Prostate Cancer: Efficacy, Trials, and Combination Therapies ...

The meeting featured international societies and the first Spanish language abstract session, enhancing global collaboration in sexual medicine. Instructional courses covered topics like androgens, ...

Bone scans have been the standard for staging metastatic prostate cancer due to their ability to detect bone metastases indirectly. PSMA-PET offers superior specificity and accuracy compared to bone ...

Disparities in BPH treatment reimbursement across Canada may affect the adoption of new technologies and influence treatment choices. Current reimbursement models may lead to potential misuse and ...

Lu-PSMA-I&T significantly extended rPFS in PSMA-positive mCRPC patients compared to hormone therapy in the ECLIPSE trial. The trial enrolled over 400 patients globally, with primary and secondary ...

Clarity Pharmaceuticals and Nucleus RadioPharma collaborate to develop Cu-SAR-bisPSMA for mCRPC treatment in the SECuRE trial. The SECuRE trial's cohort 4 shows promising safety and efficacy, with no ...